Altimmune (ALT) Reports First Patient Dosing in Phase 1b Clinical Trial of NasoShield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Pre-Open Stock Movers 06/29: (KNSA) (WKHS) (COTY) Higher; (ICPT) (HRTX) (BYND) Lower (more...)
June 29, 2020 9:31 AM EDTToday's Pre-Open Stock Movers
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) 38.4% LOWER; announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for obeticholic acid (OCA) for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).
Heron Therapeutics, Inc. (Nasdaq: HRTX) 34.5% LOWER; announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on June 26, 2020 regarding its New Drug Application (NDA)... More
Altimmune (ALT) Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID in Outpatients with Early COVID-19
June 29, 2020 7:10 AM EDTAltimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it was awarded $4.7 million from the U.S. Army Medical Research & Development Command (USAMRDC) to fund its Phase 1/2 clinical trial of T-COVID, an investigational intranasal immune modulator for the treatment of outpatients with early COVID-19. The competitive award was granted by USAMRDC in collaboration with the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium working in partnership with the Department of Defense (DoD). The award is expected to provide Altimmune sufficient funding to cover the entire cost of conducting this clinical trial.
... More
Pre-Open Stock Movers 06/26: (MDCA) (VXRT) (GPS) Higher; (SHIP) (SOLY) (NKE) Lower (more...)
June 26, 2020 9:28 AM EDTPre-Open Stock Movers:
MDC Partners Inc. (NASDAQ: MDCA) 146% HIGHER; announced that its Board of Directors has formed a special committee of independent directors to review the preliminary, non-binding proposal made by Stagwell Media LP with respect to a potential business combination between the Company and Stagwell. Mark Penn, Chairman and Chief Executive Officer of the Company, is also the managing partner of Stagwell. The special committee has not reached any conclusion as to the advisability or feasibility of a Potential Transaction.
Vaxart (NASDAQ:... More
